Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance)

Author:

Brown Justin C123ORCID,Ma Chao4,Shi Qian5ORCID,Couture Felix6,Kuebler Philip7,Kumar Pankaj8,Tan Benjamin9,Krishnamurthi Smitha10,Chang Victor11ORCID,Goldberg Richard M12,O’Reilly Eileen M13,Shields Anthony F14ORCID,Meyerhardt Jeffrey A4

Affiliation:

1. Pennington Biomedical Research Center , Baton Rouge, LA, USA

2. New Orleans School of Medicine, Louisiana State University Health Sciences Center , New Orleans, LA, USA

3. Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center , New Orleans, LA, USA

4. Dana-Farber Cancer Institute , Boston, MA, USA

5. Alliance Statistics and Data Management Center, Mayo Clinic , Rochester, MN, USA

6. Hôtel-Dieu de Québec , Québec, Canada

7. Columbus National Cancer Institute Community Oncology Research Program , Columbus, OH, USA

8. Heartland Cancer Research NCI Community Oncology Research Program, Illinois CancerCare PC , Peoria, IL, USA

9. Siteman Cancer Center, Washington University School of Medicine , Saint Louis, MO, USA

10. Cleveland Clinic , Cleveland, OH, USA

11. Veterans Administration New Jersey Health Care System , East Orange, NJ, USA

12. West Virginia University Cancer Institute , Morgantown, WV, USA

13. Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center , New York, NY, USA

14. Karmanos Cancer Institute, Wayne State University , MI, USA

Abstract

Abstract Background Inflammation and insufficient physical inactivity contribute to individual-level risk of disease recurrence and death in stage III colon cancer. The extent to which increased inflammatory risk can be offset by sufficient physical activity remains unknown. Methods This cohort study was nested within the Cancer and Leukemia Group B (now part of the Alliance for Clinical Trials in Oncology) and Southwest Oncology Group randomized trial. Inflammatory burden was quantified by high-sensitivity C-reactive protein, interleukin-6, and soluble tumor necrosis factor-α receptor 2 after recovery from tumor resection. Physical activity was measured during and after postoperative chemotherapy. The primary endpoint was disease-free survival. Results The 3-year disease-free survival rate was 88.4% among patients with low inflammation and sufficient physical activity (referent group for all comparisons), 84.9% with low inflammation and insufficient physical activity (absolute risk difference = −3.5 percentage points, 95% confidence interval [CI] = −11.3 to 4.3; P = .38), 78.0% with intermediate inflammation and insufficient physical activity (absolute risk difference = −10.4 percentage points, 95% CI = −17.4 to −3.3; P = .007), and 79.7% with high inflammation and insufficient physical activity (absolute risk difference = −8.7 percentage points, 95% CI = −15.7 to −1.6; P = .022). In contrast, the 3-year disease-free survival rate was 87.3% among patients with intermediate inflammation and sufficient physical activity (absolute risk difference = −1.1 percentage points, 95% CI = −7.5 to 5.3; P = .74) and 84.4% with high inflammation and sufficient physical activity (absolute risk difference = −4.0 percentage points, 95% CI = −12.3 to 4.3; P = .34). Conclusion In this observational study of stage III colon cancer patients, physical activity was associated with improved disease-free survival despite high inflammation. Patients with intermediate or high inflammation who were physically active had disease-free survival rates that were not statistically significantly different from those with low inflammation.

Funder

National Cancer Institute

National Institutes of Health

Alliance for Clinical Trials in Oncology

Canadian Cancer Trials Group

ECOG–ACRIN Cancer Research Group

NRG Oncology

SWOG Cancer Research Group

Pfizer. Dr Brown

Douglas Gray Woodruff Chair

Guo Shu Shi Fund

Anonymous Family Fund for Innovations in Colorectal Cancer

George Stone Family Foundation

American Institute for Cancer Research

Cancer Research UK

Celgene–Bristol Myers Squibb and Roche/Genentech

Columbus National Community Oncology Research Program

National Institutes of Cancer

Astra Zeneca

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3